Skip to main content
. 2020 Feb 3;22(5):743–754. doi: 10.1111/dom.13963

Figure 2.

Figure 2

Pharmacodynamic action profiles (glucose infusion rate) in clamp studies (fasting) after subcutaneous injection of (A) faster aspart [adapted from Heise et al52 under Creative Commons Attribution‐NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/)], (B) ultra‐rapid lispro (adapted from Leohr et al35) and (C) BioChaperone Lispro (adapted from Andersen et al47), all versus insulin aspart or lispro in healthy volunteers or people with type 1 diabetes